CLINICAL TRIALS PROFILE FOR SHR3680
✉ Email this page to a colleague
Clinical Trials for SHR3680
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02691975 ↗ | A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients | Active, not recruiting | Jiangsu HengRui Medicine Co., Ltd. | Phase 1/Phase 2 | This study evaluates the tolerability, safety, pharmacokinetics and efficacy of SHR3680 in patients with metastatic castration-resistant prostate cancer (mCPRC). All participants will receive SHR3680. |
NCT02747342 ↗ | A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer | Completed | Atridia Pty Ltd. | Phase 1 | This is a multicenter, dose-escalation/expansion phase 1 trial to evaluate the safety, tolerability and efficacy of SHR3680 with or without SHR3162 given orally to subjects with metastatic castration-resistant prostate cancer (mCRPC). |
NCT03520478 ↗ | A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer | Active, not recruiting | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | The aim of this study is to compare the safety and efficacy of SHR3680 with bicalutamide in the treatment of patients with hormone sensitive prostate cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for SHR3680
Condition Name
Clinical Trial Locations for SHR3680
Clinical Trial Progress for SHR3680
Clinical Trial Phase
Clinical Trial Sponsors for SHR3680
Sponsor Name